Pasithea Therapeutics (KTTA) Competitors $0.93 -0.01 (-1.17%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. BGXX, CSCI, HOTH, LSB, PHXM, TLPH, CYCN, ATHA, DWTX, and HCWBShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Bright Green (BGXX), COSCIENS Biopharma (CSCI), Hoth Therapeutics (HOTH), Lakeshore Biopharma (LSB), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Cyclerion Therapeutics (CYCN), Athira Pharma (ATHA), Dogwood Therapeutics (DWTX), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Bright Green COSCIENS Biopharma Hoth Therapeutics Lakeshore Biopharma PHAXIAM Therapeutics Talphera Cyclerion Therapeutics Athira Pharma Dogwood Therapeutics HCW Biologics Pasithea Therapeutics (NASDAQ:KTTA) and Bright Green (NASDAQ:BGXX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Which has more risk and volatility, KTTA or BGXX? Pasithea Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Bright Green has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Do insiders & institutionals believe in KTTA or BGXX? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of Bright Green shares are owned by institutional investors. 16.3% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 62.5% of Bright Green shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, KTTA or BGXX? Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Bright Green, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$15.96M-$10.60-0.09Bright GreenN/AN/A-$13.13M-$0.06N/A Does the MarketBeat Community favor KTTA or BGXX? Pasithea Therapeutics received 2 more outperform votes than Bright Green when rated by MarketBeat users. CompanyUnderperformOutperformPasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Bright GreenN/AN/A Does the media favor KTTA or BGXX? In the previous week, Pasithea Therapeutics had 3 more articles in the media than Bright Green. MarketBeat recorded 4 mentions for Pasithea Therapeutics and 1 mentions for Bright Green. Bright Green's average media sentiment score of 0.95 beat Pasithea Therapeutics' score of 0.42 indicating that Bright Green is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Green 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KTTA or BGXX more profitable? Pasithea Therapeutics' return on equity of -81.57% beat Bright Green's return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -81.57% -74.31% Bright Green N/A -88.37%-55.30% SummaryPasithea Therapeutics beats Bright Green on 6 of the 11 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.78M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.099.0626.7719.70Price / SalesN/A259.83393.27122.35Price / CashN/A65.8538.2534.62Price / Book0.046.456.774.50Net Income-$15.96M$143.98M$3.23B$248.22M7 Day Performance-1.57%0.38%0.43%-0.80%1 Month Performance-42.27%2.14%9.07%11.52%1 Year Performance-85.52%-0.33%18.57%8.99% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.5901 of 5 stars$0.93-1.2%N/A-85.7%$2.75MN/A-0.093BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownCSCICOSCIENS BiopharmaN/A$3.60-0.1%N/AN/A$11.31M$9.59M-0.3020Gap DownHOTHHoth Therapeutics2.7239 of 5 stars$0.85-0.5%$4.00+372.9%-30.0%$11.17MN/A-0.644Analyst DowngradeGap DownLSBLakeshore Biopharma0.703 of 5 stars$1.15+1.8%N/AN/A$10.70M$672.27M0.00773PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049TLPHTalphera2.7403 of 5 stars$0.52+1.1%$5.00+869.7%-50.6%$10.57M$281,000.00-0.7519Gap DownCYCNCyclerion Therapeutics0.8126 of 5 stars$3.28+5.5%N/A+19.9%$10.53M$2.08M-2.8330ATHAAthira Pharma1.6826 of 5 stars$0.27-1.4%$13.83+5,059.8%-89.7%$10.47MN/A-0.0940Gap DownDWTXDogwood Therapeutics1.1779 of 5 stars$5.47-4.2%$10.00+82.8%N/A$10.45MN/A-0.845Gap DownHCWBHCW Biologics1.3484 of 5 stars$9.18+7.1%N/A-81.3%$10.31M$2.57M-9.1840 Related Companies and Tools Related Companies Bright Green Alternatives COSCIENS Biopharma Alternatives Hoth Therapeutics Alternatives Lakeshore Biopharma Alternatives PHAXIAM Therapeutics Alternatives Talphera Alternatives Cyclerion Therapeutics Alternatives Athira Pharma Alternatives Dogwood Therapeutics Alternatives HCW Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTA Stock Free KTTA Stock Alerts